	US 12,403,188 B2
	Bordetella strains expressing serotype 3 fimbriae
Anne-Sophie Debrie, La Madeleine (FR); Dominique Raze, Gruson (FR); and Camille Locht, Brussels (BE)
Filed by Institut Pasteur de Lille, Lille (FR); and Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR)
Filed on Aug. 3, 2022, as Appl. No. 17/817,272.
Application 17/817,272 is a division of application No. 16/848,793, filed on Apr. 14, 2020, granted, now 11,446,372.
Application 16/848,793 is a continuation of application No. PCT/EP2018/078522, filed on Oct. 18, 2018.
Claims priority of provisional application 62/574,068, filed on Oct. 18, 2017.
Prior Publication US 2022/0362369 A1, Nov. 17, 2022
Int. Cl. A61K 39/10 (2006.01); A61K 39/02 (2006.01); A61P 31/04 (2006.01); C12P 21/06 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/099 (2013.01) [A61P 31/04 (2018.01); A61K 2039/522 (2013.01)]

6 Claims

1. A vaccine comprising a pharmaceutically acceptable carrier and a live attenuated Bordetella pertussis strain engineered to stably produce Fim3, wherein the live attenuated Bordetella pertussis strain retains the ability to colonize a mammalian subject's lungs and induce a protective immune response against Bordetella infection by Bordetella pertussis or Bordetella parapertussis, wherein the live attenuated Bordetella strain also stably produces Fim2.